Status:
UNKNOWN
Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute
Conditions:
Lung Transplant; Complications
Eligibility:
All Genders
18-100 years
Brief Summary
Background: Lung transplant recipients (LTR) have the highest risk of CMV infection. CMV pneumonitis, lymphocytic bronchitis, and detection of CMV DNA in bronchoalveolar lavage fluid are independent r...
Eligibility Criteria
Inclusion
- · Survival \> 1 month post-transplant
- • High to moderate risk patients to develop CMV disease by means of pre-transplant CMV serology:
- Donor positive to recipient negative
- Recipient positive independently of donor serology
Exclusion
- Survival \< 1 month after procedure
- Low risk serology to develop CMV disease: both donor and recipient seronegative
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04377139
Start Date
June 1 2020
End Date
June 1 2022
Last Update
May 11 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.